State Street
INTS icon

State Street’s Intensity Therapeutics INTS Stock Holding History

State Street’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,448
Closed -$55.9K – 4307
2025
Q4 		$55.9K Buy
5,448
+4,868
+839% +$49.4K ﹤0.01% 4136
2025
Q3 		$3.52K Hold
580
– – ﹤0.01% 4278
2025
Q2 		$4.45K Hold
580
– – ﹤0.01% 4254
2025
Q1 		$28.6K Hold
580
– – ﹤0.01% 4164
2024
Q4 		$25.7K Hold
580
– – ﹤0.01% 4204
2024
Q3 		$55.4K Hold
580
– – ﹤0.01% 4084
2024
Q2 		$71K Hold
580
– – ﹤0.01% 4084
2024
Q1 		$75.4K Hold
580
– – ﹤0.01% 4084
2023
Q4 		$124K Buy
+580
New +$61.1K ﹤0.01% 4008

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street's INTS Position: Q1 2026 in Review

State Street sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 5,448 shares — an estimated $55.9K sold.

State Street first reported a position in INTS in Q4 2023 and held it in 9 quarters. The position peaked at $124K in Q4 2023. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • State Street reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • State Street sold 5,448 Intensity Therapeutics shares in Q1 2026, an estimated $55.9K.
  • State Street first reported a position in Intensity Therapeutics in Q4 2023 and held it in 9 quarters.
  • State Street's Intensity Therapeutics position peaked at $124K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.